Aegerion Pharmaceuticals, Inc. an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the issuance of Patent No. 7,932,268 for lomitapide for “Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects” by the United States Patent and Trademark Office.

The patent relates specifically to the treatment of hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia, using step-wise, increasing doses of lomitapide. Such dosing regimens are an essential component of Aegerion's development of lomitapide and other MTP inhibitors. The patent extends until August of 2027 and may be eligible for listing in the US Food and Drug Administration Orange Book.  This patent application has been filed broadly in major markets, and is currently pending or issued in other jurisdictions.

“This is an important milestone for Aegerion,” commented Marc D Beer, chief executive officer of Aegerion, “and we are most appreciative of Dr Daniel Radar of the University of Pennsylvania, the inventor of the patent.” Beer continued, “This patent is an important addition to the Aegerion intellectual property portfolio as titrating the doses enables lomitapide to be used at maximum efficacy while maintaining the highest tolerability profile for the patient. It has the potential to extend patent protection on the use of lomitapide to August 2027.”